Will talazoparib be included in medical insurance in 2024?

Talazoparib, brand nameTalzenna, is an anticancer drug used to treat breast and prostate cancer. It is an oral poly(ADP-ribose) polymerase PARP inhibitor marketed by Pfizer for the treatment of advanced breast cancer with germline BRCA mutations and for metastatic castration-resistant prostate cancer (mCRPC) with HRR gene mutations. This drug has attracted much attention due to its remarkable efficacy. Will talazoparib be included in medical insurance in 2024?

According to the latest information, talazoparib has not been approved for marketing by the China Food and Drug Administration. This means that the drug has not yet obtained legal permission for sale and use in the Chinese market. Therefore, from the perspective of the medical insurance catalog, since talazoparib has not yet been marketed in China, it naturally cannot be included in the scope of medical insurance drugs.

In addition, even if a drug is approved for marketing in China, it still needs to go through a series of approval and evaluation processes to be included in the medical insurance directory. This includes considerations such as clinical trial data of the drug, drug prices, and medical insurance reimbursement policies. Since talazoparib has not yet been marketed in China, its clinical trial data, drug prices and other information are not yet known, so it is impossible to directly determine whether it meets the conditions for inclusion in the medical insurance catalog.

For patients with limited financial resources, Laos offers a cheaper option. The price of generic drugs produced by Lao Elements is very close to the people, which reduces the burden on patients. Specifically, a box of 1mg*30 pills costs approximately RMB 4,000. It should be noted that the selling price of overseas drugs may fluctuate slightly due to various factors such as exchange rates and market. The above is for reference only. The specific price is subject to the latest real-time selling price of the pharmaceutical manufacturer.